Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors

Alessandro Busca, Anna Novarino, Paolo De Fabritiis, Alessandra Picardi, Massimo Zeuli, Franco Locatelli, Oscar Bertetto, Michele Falda

Risultato della ricerca: Contributo in rivistaArticolo in rivista

Abstract

Background: The aim of the study was to evaluate the feasibility and efficacy of a non-myeloablative regimen to achieve complete donor chimerism after stem cell transplantation (SCT) in patients with metastatic solid tumors.Patients and methods: Seven patients with renal cell carcinoma (RCC), 3 with colorectal carcinoma and 1 with soft tissue sarcoma received an allogeneic SCT after fludarabine ( 90 mg/m(2)) and TBI 200 cGy.Results: At day 30, median donor chimerism was 94%. Regression of tumor metastases has been observed in 1 patient with RCC. Overall, 8 patients (73%) died from progressive disease ( median progression-free survival 3.7 months) and 1 (9%) from treatment-related complications; 2 patients were alive 152 and 862 days after transplantation.Conclusions: Our preliminary results suggest that non-myeloablative SCT for metastatic solid tumors is feasible, although may lead to durable responses in a minority of patients. Careful patient selection seems to be mandatory in this transplant setting.
Lingua originaleEnglish
pagine (da-a)171-177
Numero di pagine8
RivistaHematology
Volume11
DOI
Stato di pubblicazionePubblicato - 2006

Keywords

  • nonmyeloablative regimen
  • solid tumors
  • graft versus tumor effect
  • allogeneic stem cell transplantation

Fingerprint

Entra nei temi di ricerca di 'Nonmyeloablative allogeneic blood stem cell transplantation in patients with metastatic solid tumors'. Insieme formano una fingerprint unica.

Cita questo